Early Changes in Incretin Secretion After Laparoscopic Duodenal–Jejunal Bypass Surgery in Type 2 Diabetic Patients
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
A stomach-preserving duodenal–jejunal bypass (DJB) has been used for the treatment of type 2 diabetes mellitus (DM) since Rubino et al. first reported a prospective trial. However, there has been no report on changes in incretin secretion after DJB. We aimed to investigate whether DJB changes incretin secretion in nonmorbidly obese type 2 diabetic patients.
The inclusion criteria in this prospective study were: patient age of 20–65 years, body mass index of <30 kg/m2, a history of type 2 DM for ≤10 years, and fasting C-peptide ≥0.3 nmol/l. Six patients with type 2 DM without morbid obesity underwent DJB. Fasting plasma glucose and glycated hemoglobin (HbA1c) were measured. An oral glucose tolerance test (OGTT) was performed with measurement of glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), insulin, C-peptide, and glucagon. The study subjects were followed up for 6 months.
The body weight of patients declined after surgery. The area under the curve (AUC) of glucose, peak glucose levels during OGTT, and HbA1c also declined until 3 months postoperatively. The AUC of C-peptide and insulin tended to increase postoperatively. The AUC of glucagon had a significant increase at 6 months postoperatively. The AUC of active GLP-1 increased at 1 month and at 6 months postoperatively. There was no change in the AUC of total GIP.
Our data suggest that DJB increases GLP-1 secretion in nonmorbidly obese type 2 diabetic patients. However, long-term data are needed to confirm this finding.
- King H, Aubert R, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diab Care. 1998;21:1414–31. CrossRef
- Zimmet P, Alberti K, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–7. CrossRef
- Bloomgarden ZT. Diabetes and obesity: part 1. Diab Care. 2007;30:3145–51. CrossRef
- Rubino F, Marescaux J. Effect of duodenal–jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;239:1–11. CrossRef
- Cohen RV, Schiavon CA, Pinheiro JS, et al. Duodenal–jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22–34 kg/m2: a report of 2 cases. Surg Obes Relat Dis. 2007;3:195–7. CrossRef
- Shafrir E. Development and consequences of insulin resistance: lessons from animals with hyperinsulinaemia. Diab Metab. 1997;22:131–48.
- Detournay B, Cross S, Charbonnel B, et al. Managing type 2 diabetes in France: the ECODIA survey. Diab Metab. 2000;26:363–9.
- Scopinaro N, Marinari G, Camerini GB, et al. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study. Diab Care. 2005;28:2406–11. CrossRef
- Tejirian T, Jensen C, Dutson E. Bariatric surgery and type 2 diabetes mellitus: surgically induced remission. J Diab Sci Technol. 2008;2:685–91.
- Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;13:1724–37. CrossRef
- Mingrone G, Castagneto-Gissey L. Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery. Diab Metab. 2009;35:518–23. CrossRef
- Rubino F, Gagner M. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg. 2002;236:554–9. CrossRef
- Patriti A, Facchiano E, Sanna A, et al. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obes Surg. 2004;14:840–8. CrossRef
- Buchwald H, Estok R, Fahrbach K et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009;122:248–56.e245.
- Gumbs AA, Modin I, Ballantyne GH. Changes in insulin resistance following bariatric surgery: role of caloric restriction and weight loss. Obes Surg. 2005;15:462–73. CrossRef
- Lin E, Davis S, Srinivasan J, et al. Dual mechanism for type-2 diabetes resolution after Roux-en-Y gastric bypass. Am Surg. 2009;75:498–502.
- Rubino F, Forgione A, Cummings D, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741–9. CrossRef
- Laferrère B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diab Care. 2007;30:1709–16. CrossRef
- Mingrone G, DeGaetano A, Greco AV, et al. Reversibility of insulin resistance in obese diabetic patients: role of plasma lipids. Diabetologia. 1997;40:599–605. CrossRef
- Noya G, Cossu M, Coppola M, et al. Biliopancreatic diversion preserving the stomach and pylorus in the treatment of hypercholesterolemia and diabetes type II: results in the first 10 cases. Obes Surg. 1998;8:67–72. CrossRef
- Early Changes in Incretin Secretion After Laparoscopic Duodenal–Jejunal Bypass Surgery in Type 2 Diabetic Patients
Volume 20, Issue 11 , pp 1530-1535
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Duodenal–jejunal bypass
- Metabolic surgery
- Type 2 diabetes mellitus
- Industry Sectors
- Author Affiliations
- 1. Department of Surgery, The Catholic University of Korea, Seoul, Korea
- 2. Department of Internal Medicine, The Catholic University of Korea, Yeouido St. Mary’s Hospital, 62 Yeouido-dong, Youngdeungpo-gu, Seoul, 150-713, Korea